Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

LCTX vs CYPH: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CYPH Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 9–1 Matrix Metrics)

CYPH Overall Winner 6-Pillar Tally: LCTX 2 – 3 CYPH (1 Tie) Matrix Metrics: LCTX 1 – 9 CYPH

As of Nov 19, 2026, Cypherpunk Technologies Inc. (CYPH) is the stronger overall head-to-head candidate over Lineage Cell Therapeutics, Inc. (LCTX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LCTX carries a Unified Composite Score of 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin), whereas CYPH carries 67.5/100 (BUY) at $1.72 (2.6x Forward P/E, -122.7% operating margin).

  • Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3); meanwhile CYPH is in a Breakdown options structure phase (RSI 38.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LCTX vs CYPH
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.36β · 79% Vol
Unified Composite Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.2%), weak momentum, RSI 38
RSI-14: 38.3 · SMA20: $0.98 · SMA50: $0.98
CYPH US Equity Head-to-Head Winner
Cypherpunk Technologies Inc.
Pharmaceutical Preparations
$1.72
-1.71% 1D
Market Cap $260.8M
TTM Revenue $9.9M
Forward P/E 2.6x
Beta / 30D Vol 4.67β · 151% Vol
Unified Composite Score
67.5 / 100 BUY
Tech 70.0 Fund 63.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 38
RSI-14: 38.0 · SMA20: $2.46 · SMA50: $2.82

6-Pillar Scorecard Institutional Category Breakdown (LCTX 2 – 3 CYPH)

Columns: Metric · LCTX · CYPH
1. Valuation Multiples CYPH
Forward P/E 30.7x 2.6x
Trailing P/E 30.7x 0.8x
PEG Ratio 10.64x N/M
EV / Revenue 16.3x 25.5x
2. Growth & Scale CYPH
Revenue Growth (YoY) -61.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M $9.9M
Market Cap $212.1M $260.8M
3. Profitability & Quality CYPH
Gross Margin -95.0% 90.6%
Operating Margin -280.3% -122.7%
Net Profit Margin 16.2% 3111.4%
Return on Equity (ROE) 4.3% 114.6%
4. Balance Sheet & Cash Flow LCTX
Cash Generation (TTM) -$24M -$132M
Cash Flow Margin N/A N/A
Net Cash / Leverage $35M Net Cash $7.6M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning LCTX
Options Structure Phase BREAKDOWN BREAKDOWN
Current IV / %ile 896.2% (100th %ile) 276.2% (27th %ile)
Put/Call OI Skew 1.10x (Balanced) 1.00x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Asset Management Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LCTX (1) vs CYPH (9)
Institutional Metric LCTX CYPH Criterion Row Edge
Market Capitalization
Scale
$212.1M $260.8M Larger Scale CYPH
Trailing P/E Ratio
Valuation
30.7x 0.8x Lower Multiple CYPH
Forward P/E Ratio
Valuation
30.7x 2.6x Lower Multiple CYPH
Revenue Growth (YoY)
Growth
-61.0% +0.0% Higher Growth CYPH
Operating Margin (TTM)
Profitability
-280.3% -122.7% Higher Margin CYPH
Net Profit Margin
Profitability
16.2% 3111.4% Higher Margin CYPH
Return on Equity (ROE)
Capital Efficiency
4.3% 114.6% Higher ROE CYPH
52-Week Range Position
Momentum
4% ($1–$2) 33% ($0–$4) Stronger Trend CYPH
Beta / 30D Volatility
Risk Regime
1.36β · 79% Vol 4.67β · 151% Vol Lower Realized Risk LCTX
Unified Institutional Score
Composite Signal
58.9 / 100 (HOLD) 67.5 / 100 (BUY) Higher Composite CYPH
Trailing 12M Revenue (USD)
Operating Scale
$11M $9.9M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-95.0% 90.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
10.64x PEG · 16.3x EV/Rev N/M PEG · 25.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($35M Net Cash) -$132M ($7.6M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LCTX +34.53 pp
LCTX: -13.82% · CYPH: -48.35%
3M Horizon CYPH +45.2 pp
LCTX: -24.07% · CYPH: +21.13%
6M Horizon CYPH +69.18 pp
LCTX: -37.88% · CYPH: +31.3%
1Y Horizon CYPH +11.58 pp
LCTX: -53.67% · CYPH: -42.09%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LCTX Revenue CYPH Revenue LCTX Op. Margin CYPH Op. Margin Margin Leader
FY2018 $0M N/A -837.9% N/A LCTX
FY2019 $0M N/A -1106.0% N/A LCTX
FY2020 $0M $0M -1448.4% -1902.6% LCTX
FY2021 $0M $0M -1133.6% -2761.7% LCTX
FY2022 $10M N/A -153.2% N/A LCTX
FY2023 $10M N/A -276.5% N/A LCTX
FY2024 $10M N/A -226.1% N/A LCTX
FY2025 $10M N/A -251.6% N/A LCTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LCTX BREAKDOWN
6d in phase · OBV DISTRIBUTION
Current IV 896.2%
IV Percentile 100th %ile
Put/Call OI Skew 1.10x (Balanced)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CYPH BREAKDOWN
39d in phase · OBV DISTRIBUTION
Current IV 276.2%
IV Percentile 27th %ile
Put/Call OI Skew 1.00x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact CYPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $212.1M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
CYPH Moat Profile High-Margin Pricing Power Moat
Asset Management Operator
Competes within the Asset Management value chain with $260.8M market capitalization and -122.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LCTX vs CYPH Key Questions & Quantitative Answers

As of Nov 19, 2026, Cypherpunk Technologies Inc. (CYPH) is the stronger overall head-to-head candidate over Lineage Cell Therapeutics, Inc. (LCTX) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). LCTX carries a Unified Composite Score of 58.9/100 (HOLD) at $0.82 (30.7x Forward P/E, -280.3% operating margin), whereas CYPH carries 67.5/100 (BUY) at $1.72 (2.6x Forward P/E, -122.7% operating margin). Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 38.3); meanwhile CYPH is in a Breakdown options structure phase (RSI 38.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CYPH leads the Growth & Scale pillar: LCTX posts -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin), compared with CYPH at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $9.9M TTM revenue (90.6% gross margin, -122.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LCTX cumulative revenue shifted +0.0% while CYPH shifted N/A. In operating R&D and SG&A reinvestment, LCTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CYPH.

CYPH screens cheaper on headline valuation multiples. LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 16.3x EV/Revenue (unreported FCF margin), whereas CYPH trades at 2.6x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 25.5x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LCTX (4.3% ROE) versus CYPH (114.6% ROE) capital efficiency.

In options market volatility and institutional positioning, LCTX carries 896.2% implied volatility (100th %ile, Extreme (>80th %ile)), a 1.10x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.36β · 79% Vol realized risk). By comparison, CYPH carries 276.2% implied volatility (27th %ile, Balanced (25th–60th %ile)), a 1.00x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (4.67β · 151% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.